




RealRate

PHARMACEUTICAL 2020

Cogent Biosciences Inc.
Rank 193 of 358





RealRate

PHARMACEUTICAL 2020

Cogent Biosciences Inc.
Rank 193 of 358



The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Cogent Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 32% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	40,591
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,248
Liabilities, Non-Current	4,413
Other Assets	6,967
Other Compr. Net Income	12
Other Expenses	0
Other Liabilities	0
Other Net Income	345
Other Revenues	22,499
Property and Equipment	1,865
Research and Development	43,709
Selling, General and Administrative Expense	10,968

Output Variable	Value in 1000 USD
Assets	49,423
Liabilities	17,661
Expenses	54,677
Revenues	22,499
Stockholders Equity	31,762
Net Income	-31,833
Comprehensive Net Income	-31,827
Economic Capital Ratio	68%